Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03454035 | Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | PHASE1 | RECRUITING | 45 | — | — | Jan 30, 2018 | Nov 24, 2026 | Sep 11, 2025 | 1 | United States |
MTD of ulixertinib in combination with palbociclib in patients with advanced solid tumors of ulixertinib in combination with palbociclib in patients with advanced solid tumors
For Expansion Cohort: To estimate overall survival (OS) after treatment with the recommended phase 2 dose of ulixertinib in combination with palbociclib in an expansion cohort of patients with metastatic pancreatic cancer
| Arm | Type | Description |
|---|---|---|
| Open-label, single arm Phase I | EXPERIMENTAL | Ulixertinib added to palbociclib |
| Name | Type | Description |
|---|---|---|
| Ulixertinib | DRUG | Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib |
| Palbociclib | DRUG | Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib |
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. 2. Age ≥ 18 years at the time of consent (no upper age limit) 3. Eastern Cooperative Oncology...